| 产品描述: | MYLS22 是一种选择性的 optic atrophy 1 (OPA1) 抑制剂,具有抗血管生成和抗癌活性 |
| 体外研究: |
Opa1 inhibitor MYLS22 can result in higher maximal and residual cytoplasmic calcium levels, and alter T cell receptor (TCR) signaling in thymocytes with higher susceptibility to apoptosis |
| 体内研究: |
MYLS22, a small molecule first-in-kind Opa1-specific inhibitor, can affect angiogenesis, tumor growth and metastasis by impinging on NF-κB activity and on angiogenic gene expression. |
| 细胞实验: |
Cell lines: Jurkat cells Concentrations: 50 μM Incubation Time: 2 h Method: Jurkat cells are cultured in 1640 media supplemented with 10% FCS, 4 mM L-glutamine, 1 penicillin/streptomycin, and 55 μM β-mercaptoethanol under 5% CO2, atmospheric oxygen, at 37 °C in a humidified incubator. For MYLS22 treatment, cells are ished and resuspended in RPMI supplemented with 2% FCS and 50 μM MYLS22 for 2 h before the experiment is started.The treated cells are used for Calcium measurements, Flow cytometry, Electron microscopy, and Western blotting. |
| 动物实验: |
Animal Models: C57BL6/J mice(Opa1+/ΔEC, Opa1iΔEC, Opa1+/iΔEC, Opa1+/ΔEC, Mfn1iΔEC) Dosages: 10 mg/kg Administration: i.p. |
| 参考文献: |
1. Stéphanie Herkenne, et al. Developmental and Tumor Angiogenesis Requires the Mitochondria-Shaping Protein Opa1. Cell Metab. 2020 May 5;31(5):987-1003.e8. 2. Corrado M, et al. Deletion of the mitochondria-shaping protein Opa1 during early thymocyte maturation impacts mature memory T cell metabolism. Cell Death Differ. 2021 Jul; 28(7): 2194–2206. |
| 溶解性: |
Soluble in DMSO |
| 保存条件: |
-20℃ |
| 配置溶液浓度参考: |
|
1mg |
5mg |
10mg |
| 1 mM |
2.255 ml |
11.273 ml |
22.547 ml |
| 5 mM |
0.451 ml |
2.255 ml |
4.509 ml |
| 10 mM |
0.225 ml |
1.127 ml |
2.255 ml |
| 50 mM |
0.045 ml |
0.225 ml |
0.451 ml |
|
| 注意: |
部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,仅供客户参考交流研究之用。 |